The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2020 | AML: what to look forward to at ASH 2020
Thomas Prebet, MD, PhD, Yale School of Medicine, New Haven, CT, outlines what he’s looking forward to at this year’s virtual ASH conference. This includes greater insight into the management of molecularly-defined disease and new agents that are rising as potentially active treatments for acute myeloid leukemia (AML). This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Thomas Prebet, MD, PhD, has done consultancy work for BMS and AbbVie and has received research support from BMS and Jazz.
